YangPan

YangPan is a clinical-stage biotechnology company specializing in the development of non-invasive deep brain stimulation (dBS) technologies. The company's proprietary platform utilizes Temporal Interference Stimulation (TIS) to precisely modulate deep-seated neural circuits, such as the amygdala and hippocampus, without the need for invasive surgery. YangPan is currently conducting multiple clinical trials for a range of neuropsychiatric and neurological conditions, including alcohol use disorder, Parkinson's disease, and drug-resistant epilepsy. By combining advanced electric field simulation with individualized neuroimaging, the company aims to provide personalized neuromodulation therapies that address significant unmet needs in brain health.